FDA user fee date for Neuromed/Covidien's Exalgo pushed back to February
This article was originally published in Scrip
Executive Summary
The US FDA has extended the user fee date for Neuromed Pharmaceuticals' long-acting opioid Exalgo (hydromorphone extended-release tablets; licensed to Covidien) by three months to February 22nd, 2010.